These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 16245237)

  • 1. Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?
    Rasche FM; Keller F; Rasche WG; Schiekofer S; Boldt A; Sack U; Fahnert J
    Clin Exp Immunol; 2016 Nov; 186(2):115-133. PubMed ID: 27283488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.
    Salvadori M; Rosso G
    World J Nephrol; 2016 Jan; 5(1):6-19. PubMed ID: 26788460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents for treating IgA nephropathy.
    Kunter U; Seikrit C; Floege J
    Curr Opin Nephrol Hypertens; 2023 Sep; 32(5):418-426. PubMed ID: 37382182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide.
    Mitsuiki K; Harada A; Okura T; Higaki J
    Clin Exp Nephrol; 2007 Dec; 11(4):297-303. PubMed ID: 18085391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of antiplatelet therapy for IgA nephropathy.
    Taji Y; Kuwahara T; Shikata S; Morimoto T
    Clin Exp Nephrol; 2006 Dec; 10(4):268-73. PubMed ID: 17186331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.
    Rasche FM; Keller F; Lepper PM; Aymanns C; Karges W; Sailer LC; Müller Lv; Czock D
    Clin Exp Immunol; 2006 Oct; 146(1):47-53. PubMed ID: 16968397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of IgA nephropathy: an update.
    Rosselli JL; Thacker SM; Karpinski JP; Petkewicz KA
    Ann Pharmacother; 2011 Oct; 45(10):1284-96. PubMed ID: 21954446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune modulating therapy for IgA nephropathy: rationale and evidence.
    Floege J; Eitner F
    Semin Nephrol; 2008 Jan; 28(1):38-47. PubMed ID: 18222345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current therapy for IgA nephropathy.
    Floege J; Eitner F
    J Am Soc Nephrol; 2011 Oct; 22(10):1785-94. PubMed ID: 21903997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F; Vecchio LD; Pozzi C
    Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F; Ackermann D; Hilgers RD; Floege J
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and future therapy options in IgA-nephropathy.
    Floege J; Eitner F
    J Nephrol; 2005; 18(4):354-61. PubMed ID: 16245237
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.